.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Nix-TB study evaluated an all-oral combination of bedaquiline, pretomanid, and linezolid in adults with extensively drug-resistant tuberculosis or treatment-intolerant or nonresponsive multidrug-resistant disease. The study reported a high proportion of participants achieving a favorable treatment outcome with a regimen that was substantially shorter than traditional courses. The findings helped establish a new treatment paradigm for difficult-to-treat drug-resistant TB, centered on potent all-oral therapy rather than prolonged injectable-based regimens. At the same time, toxicity—particularly effects associated with linezolid—was an important part of the treatment equation. For HCPs, the major lesson is that effective drug-resistant TB therapy increasingly depends on both regimen efficacy and proactive adverse-event management. Patients require structured monitoring, adherence support, and rapid action when neuropathy, myelosuppression, or other toxicities appear. The paper directly supports the conference emphasis on managing drug-resistant TB and on moving beyond regimen selection alone toward patient-centered, programmatically workable care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The Nix-TB study evaluated an all-oral combination of bedaquiline, pretomanid, and linezolid in adults with extensively drug-resistant tuberculosis or treatment-intolerant or nonresponsive multidrug-resistant disease. The study reported a high proportion of participants achieving a favorable treatment outcome with a regimen that was substantially shorter than traditional courses. The findings helped establish a new treatment paradigm for difficult-to-treat drug-resistant TB, centered on potent all-oral therapy rather than prolonged injectable-based regimens. At the same time, toxicity—particularly effects associated with linezolid—was an important part of the treatment equation. For HCPs, the major lesson is that effective drug-resistant TB therapy increasingly depends on both regimen efficacy and proactive adverse-event management. Patients require structured monitoring, adherence support, and rapid action when neuropathy, myelosuppression, or other toxicities appear. The paper directly supports the conference emphasis on managing drug-resistant TB and on moving beyond regimen selection alone toward patient-centered, programmatically workable care.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
